Perspective: How will healthcare reform affect cancer care?
In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.
In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, M.D., Ph.D, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.
Interview: news.cancerconnect.com/asco-2010-how-will-healthcare-reform-affect-cancer-care/
Perspectives and concerns about the affects of Obama-care abound…
On July, 14th the Community Oncology Alliance (COA) announced that due to severe year after year cuts to Medicare reimbursement for cancer care, community oncologists around the US are closing offices at a rate rapidly increasing since January 2010. Reductions in staff, services and facilities are also on the rise.
“As a practicing oncologist, I am extremely concerned about the impact these closings have on
patients. Many are simply falling through the cracks as providers are being forced to cut staff and
close clinics, forcing patients to seek treatments outside of their communities,” said David Eagle,
MD, newly elected President of COA.
--Look here for continuing coverage and analysis of the policies coming from Capitol Hill that directly impact the delivery of oncology services across the country.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
